<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596488</url>
  </required_header>
  <id_info>
    <org_study_id>XL001</org_study_id>
    <nct_id>NCT04596488</nct_id>
  </id_info>
  <brief_title>Efavirenz 400mg in Treatment-na誰ve Chinese HIV-infected Patients</brief_title>
  <official_title>Pharmacodynamics of Efavirenz 400mg in Treatment-na誰ve Chinese HIV-infected Patients in a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Key Technologies R&amp;D Program for the 13th Five-year Plan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Key Technologies R&amp;D Program for the 12th Five-year Plan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CAMS Initiative for Innovative Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the efficacy, pharmacodynamics, and safety of Efavirenz 400mg in treatment-na誰ve&#xD;
      Chinese HIV-infected patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment-naive HIV-infected patients are designed to enroll and receive efavirenz 400mg&#xD;
      combined with tenofovir (TDF) and lamivudine (3TC) as initial antiretroviral regimens, and&#xD;
      monitoring for 48 weeks, to evaluate efavirenz concentration, T-cell subsets, HIV RNA load,&#xD;
      and neuropsychiatric tests with Hamilton depression scale (HAMD) and Pittsburgh sleep quality&#xD;
      index (PSQI) at baseline, 4, 12, 24, 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral suppression</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of patients with viral load less than 50 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug concentration</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of patients with plasma efavirenz concentration between 1 mg/L and 4mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of patients with HAMD &lt;8 and PSQI &lt;10 (less neuropsychiatric adverse effects)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Efavirenz 400mg+TDF+3TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined antiretroviral therapy(cART) consisting of three regimens such as efavirenz, tenofovir and lamivudine is an effective measure for the treatment of HIV-1 infection.Efavirenz 600mg daily was approved by the US Food and Drug Administration in 1998. In this single-arm research, patients were treated with a reduced 400mg dose of efavirenz combined with tenofovir 300mg and lamivudine 300mg once a day. This treatment had to be maintained indefinitely due to the existence of HIV reservoir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 400mg</intervention_name>
    <description>HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.</description>
    <arm_group_label>Efavirenz 400mg+TDF+3TC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) HIV treatment-na誰ve, (2) age between 18 years or older, (3) be willing to complete&#xD;
             the HAMD and PSQI scale and follow-up regularly, (5) not participating in other&#xD;
             studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) acute HIV-1-infected patients, (2) an AIDS-defining illness such as pneumocystis&#xD;
             pneumonia, tuberculosis within 2 weeks of entry, (3) transaminase and alkaline&#xD;
             phosphatase levels beyond three times the upper limit of the normal range, bilirubin&#xD;
             level more than 2.5 times the upper limit of the normal range, and serum creatinine&#xD;
             level excess 1.5 times the upper limit of the normal range, (4) pregnancy or breast&#xD;
             feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisheng Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>LI Taisheng</investigator_full_name>
    <investigator_title>Director in department of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Efavirenz 400mg</keyword>
  <keyword>Chinese HIV-infected patients</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

